...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Combo with Enzalutamide in Phase 2 Metastatic Prostate Cancer Clinical Trial and with Pfizer’s PARPi, talazoparib, in Phase 1b/2 Triple Negative Breast Cancer Trial

Free
Message: Another IPO that shocks!

,,no I just cant see why Zenith might not look at doing a US IPO......hummmmmm

Affirm stock rockets more than 90% after IPO

Affirm Holdings Inc. shares have nearly doubled in midday trading Wednesday after the financial-technology company made its public debut.

Shares of Affirm AFRM, 101.17% opened at $90.90 Wednesday after listing on the Nasdaq, with the first trade coming at 12:20 p.m. ET. The company priced its initial public offering at $49 a share late Tuesday, above an already raised range of $41 to $44 a share. Shares recently changed hands just shy of $98.

The company raised at least $1.2 billion through the offering. Underwriters have access to an overallotment of 3.7 million shares beyond the original 24.6 million shares that Affirm sold through its IPO. Affirm reportedly delayed its IPO from late last year given the big first-day stock moves for Airbnb Inc. ABNB, 8.59% and DoorDash Inc. DASH, 5.22%

Share
New Message
Please login to post a reply